Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients With Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
April 03, 2024
April 03, 2024
WILMINGTON, Delaware, April 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. Th . . .
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. Th . . .